Thalidomide in multiple myeloma

P. Richardson, T. Hideshima, Karen Anderson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Thalidomide - removed from widespread clinical use by 1962 because of severe teratogenicity - has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha. It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma. Whilst the mechanism of action of thalidomide remains incompletely understood, considerable insight has been generated by extensive preclinical studies in multiple myeloma. Moreover, clinical trials both as a single agent and in combination have confirmed benefit in relapsed and refractory disease. Thalidomide's role in treating newly diagnosed patients is currently under study and it is now established as an important therapeutic option in the treatment of multiple myeloma.

Original languageEnglish (US)
Pages (from-to)115-128
Number of pages14
JournalBiomedicine and Pharmacotherapy
Volume56
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Thalidomide
Multiple Myeloma
Erythema Nodosum
Disease Management
Tumor Necrosis Factor-alpha
Clinical Trials
Therapeutics
Neoplasms

Keywords

  • Anti-angiogenesis
  • Immunomodulation
  • Myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Pharmacology

Cite this

Thalidomide in multiple myeloma. / Richardson, P.; Hideshima, T.; Anderson, Karen.

In: Biomedicine and Pharmacotherapy, Vol. 56, No. 3, 2002, p. 115-128.

Research output: Contribution to journalArticle

Richardson, P. ; Hideshima, T. ; Anderson, Karen. / Thalidomide in multiple myeloma. In: Biomedicine and Pharmacotherapy. 2002 ; Vol. 56, No. 3. pp. 115-128.
@article{cac44f16eb90428f89d53adc829b0bbd,
title = "Thalidomide in multiple myeloma",
abstract = "Thalidomide - removed from widespread clinical use by 1962 because of severe teratogenicity - has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha. It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma. Whilst the mechanism of action of thalidomide remains incompletely understood, considerable insight has been generated by extensive preclinical studies in multiple myeloma. Moreover, clinical trials both as a single agent and in combination have confirmed benefit in relapsed and refractory disease. Thalidomide's role in treating newly diagnosed patients is currently under study and it is now established as an important therapeutic option in the treatment of multiple myeloma.",
keywords = "Anti-angiogenesis, Immunomodulation, Myeloma, Thalidomide",
author = "P. Richardson and T. Hideshima and Karen Anderson",
year = "2002",
doi = "10.1016/S0753-3322(02)00168-3",
language = "English (US)",
volume = "56",
pages = "115--128",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "3",

}

TY - JOUR

T1 - Thalidomide in multiple myeloma

AU - Richardson, P.

AU - Hideshima, T.

AU - Anderson, Karen

PY - 2002

Y1 - 2002

N2 - Thalidomide - removed from widespread clinical use by 1962 because of severe teratogenicity - has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha. It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma. Whilst the mechanism of action of thalidomide remains incompletely understood, considerable insight has been generated by extensive preclinical studies in multiple myeloma. Moreover, clinical trials both as a single agent and in combination have confirmed benefit in relapsed and refractory disease. Thalidomide's role in treating newly diagnosed patients is currently under study and it is now established as an important therapeutic option in the treatment of multiple myeloma.

AB - Thalidomide - removed from widespread clinical use by 1962 because of severe teratogenicity - has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha. It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma. Whilst the mechanism of action of thalidomide remains incompletely understood, considerable insight has been generated by extensive preclinical studies in multiple myeloma. Moreover, clinical trials both as a single agent and in combination have confirmed benefit in relapsed and refractory disease. Thalidomide's role in treating newly diagnosed patients is currently under study and it is now established as an important therapeutic option in the treatment of multiple myeloma.

KW - Anti-angiogenesis

KW - Immunomodulation

KW - Myeloma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0036227466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036227466&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(02)00168-3

DO - 10.1016/S0753-3322(02)00168-3

M3 - Article

C2 - 12046682

AN - SCOPUS:0036227466

VL - 56

SP - 115

EP - 128

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 3

ER -